Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE) – A review

Figures & data

Table I. Demographics and clinical characteristics at baseline. Means (±SD) or per cent are given.

	Candesartan (n = 2477)	Control (n = 2460)
Women/Men (%)	64.8/35.2	64.2/35.8
Age (years)	76.4±4.5	76.4±4.5
MMSE (score)	28.5±1.6	28.5±1.5
SBP (mmHg)	166.0±8.9	166.5±9.0
DBP (mmHg)	90.3±6.5	90.4±6.6
Heart rate (beats/min)	75.3±10.0	75.4±9.9
S‐cholesterol (mmol/l)	6.3±1.2	6.2±1.2
S‐creatinine (μmol/l)	91.0±19.0	91.1±18.8
Antihypertensive therapy at enrolment (%)	52.4	53.0
Previous myocardial infarction (%)	4.5	4.6
Previous stroke (%)	3.9	3.9
Diabetes mellitus (%)	12.5	11.6
Smoker at enrolment (%)	8.7	8.7
Education
Less than primary school (%)	10.3	10.2
Primary school (%)	44.1	43.5
More than primary school (%)	39.9	40.3
University (%)	5.7	6.0

MMSE, Mini Mental State Examination; SBP, systolic blood pressure; DBP, diastolic blood pressure.

Figure 1. Distribution of therapy during the study.

Figure 2. Comparisons of event rates for cardiovascular outcomes and total mortality in all patients randomized to the candesartan or control treatment arms.

Figure 3. Comparisons of event rates for cardiovascular outcomes and total mortality in patients treated with candesartan or placebo without add‐on therapy after randomization.

Figure 4. Kaplan–Meier curves showing time to a first major cardiovascular event (cardiovascular death, non‐fatal myocardial infarction or non‐fatal stroke) for patients treated with candesartan or placebo without add‐on therapy after randomization.

Figure 5. Mean reductions in Mini Mental State Examination(MMSE) score during the study.